NCT00263744 - Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

April 30, 2001

Study Completion Date

June 30, 2001

Conditions

Healthy

Interventions

BIOLOGICAL

MEDI 517

Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.

OTHER

Aluminum hydroxide

Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.